Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

OBJECTIVE: To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy. RESEARCH DESIGN AND METHODS: This was a double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Aggarwal, Naresh, Polidori, David, Zhao, Yue, Arbit, Deborah, Usiskin, Keith, Capuano, George, Canovatchel, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357223/
https://www.ncbi.nlm.nih.gov/pubmed/22492586
http://dx.doi.org/10.2337/dc11-1926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357223/
https://www.ncbi.nlm.nih.gov/pubmed/22492586
http://dx.doi.org/10.2337/dc11-1926

Ejemplares similares